Carisbamate

Clinical data
Trade names	Comfyde (proposed)
ATC code	N03AX19 (WHO)
Identifiers
IUPAC name (S)-2-O-Carbamoyl-1-o-chlorophenyl-ethanol
CAS Number	194085-75-1 Y
PubChem CID	9942577
ChemSpider	8118189 Y
UNII	P7725I9V3Z
ChEMBL	ChEMBL2087003 N
CompTox Dashboard (EPA)	DTXSID70426076
Chemical and physical data
Formula	C9H10ClNO3
Molar mass	215.63 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccccc1(O)COC(=O)N
InChI InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m0/s1 Y Key:OLBWFRRUHYQABZ-QMMMGPOBSA-N Y
NY (what is this?)  (verify)

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.

Clinical study

A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.^[1][2]

A double-blind, placebo-controlled trial of carisbamate in 323 patients with migraine determined that carisbamate was well tolerated at doses up to 600 mg/day, but it failed to demonstrate that the drug was sufficiently more effective than placebo in migraine prophylaxis.^[3]

History

In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate.^[4] Johnson & Johnson received provisional approval by the FDA to market carisbamate under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.

References